Dermira (DERM) Tops Q1 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Dermira (DERM) Tops Q1 EPS by 13c

Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 7, 2019 4:05 PM EDT

QBREXZA (glycopyrronium) cloth prescriptions increased more than 50% over fourth quarter 2018 First quarter net product sales of $2.5 million Approximately 80% of commercially insured patients have access to QBREXZA End-of-Phase 2 FDA meeting scheduled following positive lebrikizumab study results Balance sheet strengthened through follow-on equity financing

MENLO PARK, Calif.--(BUSINESS WIRE)-- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of... More